ALKS vs. EIDX, AGIO, OPK, PCRX, AVIR, BMRN, INCY, UTHR, NBIX, and EXAS
Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Eidos Therapeutics (EIDX), Agios Pharmaceuticals (AGIO), OPKO Health (OPK), Pacira BioSciences (PCRX), Atea Pharmaceuticals (AVIR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), and Exact Sciences (EXAS). These companies are all part of the "medical" sector.
Alkermes (NASDAQ:ALKS) and Eidos Therapeutics (NASDAQ:EIDX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.
In the previous week, Alkermes had 27 more articles in the media than Eidos Therapeutics. MarketBeat recorded 27 mentions for Alkermes and 0 mentions for Eidos Therapeutics. Alkermes' average media sentiment score of 0.39 beat Eidos Therapeutics' score of 0.00 indicating that Alkermes is being referred to more favorably in the media.
Alkermes has a net margin of 19.15% compared to Eidos Therapeutics' net margin of 0.00%. Alkermes' return on equity of 23.20% beat Eidos Therapeutics' return on equity.
Alkermes has higher revenue and earnings than Eidos Therapeutics. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
95.2% of Alkermes shares are owned by institutional investors. Comparatively, 31.4% of Eidos Therapeutics shares are owned by institutional investors. 4.9% of Alkermes shares are owned by company insiders. Comparatively, 70.1% of Eidos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Alkermes received 544 more outperform votes than Eidos Therapeutics when rated by MarketBeat users. Likewise, 70.48% of users gave Alkermes an outperform vote while only 63.20% of users gave Eidos Therapeutics an outperform vote.
Alkermes currently has a consensus target price of $36.70, suggesting a potential upside of 31.64%. Given Alkermes' higher possible upside, analysts clearly believe Alkermes is more favorable than Eidos Therapeutics.
Alkermes has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Eidos Therapeutics has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500.
Summary
Alkermes beats Eidos Therapeutics on 15 of the 17 factors compared between the two stocks.
Get Alkermes News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alkermes Competitors List
Related Companies and Tools
Free ALKS Stock Alerts